Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility

Liver Transplantation

Volumn 14, Issue 4, 2008, Pages 554-562

  Castillo Rama, Marcela ^a   Castro, Maria Jose ^a   Bernardo, Ivan ^a   Meneu Diaz, Juan Carlos ^a   Elola Olaso, Almudena Moreno ^a   Calleja Antolin, Sara M ^a   Romo, Eva ^a   Morales, Pablo ^a   Moreno, Enrique ^a   Paz Artal, Estela ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DR ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CHILD; COHORT ANALYSIS; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY TEST; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HLA MATCHING; HLA TYPING; HUMAN; KAPLAN MEIER METHOD; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTIPLE BEAD ASSAY; ORGAN DONOR; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETRANSPLANTATION; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; BLOOD GROUP INCOMPATIBILITY; CHILD; COHORT STUDIES; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 42149087047     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21408     Document Type: Article

References (51)

1. Consensus conference on indications of liver transplantation. Hepatology 1994;20:S1-S68.
2. Neuberger J. Liver transplantation. J Hepatol 2000; 32(suppl 1):198-207
3. Strong RW. Liver transplantation: current status and future prospects. JR Coll Surg Edinb 2001;46:1-8.
4. Cecka JM. The changing role of HLA matching. In: Terasaki PI, ed. Clinical Kidney Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory; 1986:141.
5. Opelz G. Effect of PLA matching in 10,000 cyclosporine-treated cadaver kidney transplants. Transplant Proc 1987; 19:641.
6. Sanfilippo F, Vaughn WK, Spees EK, Light JA, LeFor WM. Benefits of HLA-A and HLA-B matching on graft and patient outcome after cadaveric-donor renal transplantation. N Engl J Med 1984;311:358.
7. Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. N Engl J Med 1994;330:816-819.
8. Nikaein A, Backman L, Jennings L, Levy M, Goldstein R, Gonwa T, et al. HLA compatibility and liver transplant outcome: improved patient survival by HLA and cross-matching. Transplant Proc 1995;127:1186-1188.
9. Lobo PI, Spencer C, Douglas MT, Stevenson WC, Pruett TL. The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies. Transplantation 1993;55:1063-1066.
10. Donaldson PT, Thomson LJ, Heads A, Underhill JA, Vaughan RW, Rolando N, et al. IgG donor-specific cross-matches are not associated with graft rejection or poor graft survival after liver transplantation. Transplantation 1995;60:1016-1023.
11. Navarro V, Herrine S, Katopes C, Colombe B, Spain CV. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. Liver Transpl 2006;12:652-658.
12. Neumann UP, Guckelberger O, Langrehr JM, Lang M, Schmitz V, Theruvath T, et al. Impact of human leukocyte antigen matching in liver transplantation. Transplantation 2003;75:132-137.
13. Nikaein A, Backman L, Jennings L, Levy MF, Goldstein R, Gonwa T, et al. HLA compatibility and liver transplant outcome. Transplantation 1994;58:786-792.
14. Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, Klintmalm G, et al. Histocompatibility and liver transplant outcome. Transplantation 1988;46:372-377.
15. Saidman SL, Ducquesnoy RJ, Demetris AJ, McCauley J, Ramos H, Mazariegos G, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994;2:61-67.
16. Watson R, Kozlowski T, Nickeleit V, Woosley JT, Schmitz JL, Zacks SL, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006;6:3022-3029.
17. Mosconi G, Scolari MP, Feliciangeli G, Zanetti A, Zanelli P, Buscaroli A, et al. Combined liver-kidney transplantation with preformed anti-HLA antibodies: a case report. Transplant Proc 2006;38:1125-1126.
18. Olausson M, Mjornstedt L, Norden G, Rydberg L, Molne J, Backman L, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007;7: 130-136.
19. Pei R, Lee J, Chen T, Rojo S, Terasaki PI. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 1999:60:1293-1302.
20. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HIA antibody detection: technology emulating biology. Immunol Res 2004;29:41-54.
21. Piazza A, Poggi E, Borrelli L, Servetti S, Monaco PI, Buonomo O, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001;71:1106-1112.
22. Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006;21: 2625-2629.
23. Mao Q, Terasaki PI, Cai J, El-Awar N, Rebellato L. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation 2007;83:54-61.
24. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: 464-470.
25. Narayanan Menon KV, Nyberg SL, Harmsen WS, DeSouza NF, Rosen CB, Krom RA, et al. MELD and other factors associated with survival after liver transplantation. Am J Transplant 2004;4:819-825.
26. Demetris AJ, Batts KP, Dhillon AP, Ferrell L, Fung J, Geller SA, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
27. Doran TJ, Geczy AF, Dorothy P, McCaughan G, Sheil AGR, Süsal C, et al. A large single center investigation of the immunogenetic factors affecting liver transplantation. Transplantation 2000;69:1491-1498.
28. Langrehr JM, Puhl G, Bahra M, Schmeding M, Spinelli A, Berg T, et al. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl 2006;12:644-651.
29. Belli LS, Zavaglia C, Alberti AB, Poli F, Rondinara G, Silini E, et al. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation. Hepatology 2000;31:1345-1350.
30. Neumann UP, Langrehr JM, Naumann U, Lang M, Rayes N, Steinmuller T, et al. Impact of HLA-compatibilities in patients undergoing liver transplantation for HBV-cirrhosis. Clin Transplant 2002;16:122-129.
31. Wong T, Donladson P, Devlin J, Roger W. Repeat HLA-B and -DR loci mismatching at second liver transplantation improves patient survival. Transplantation 1996;61:440-444.
32. Donaldson PT, Williams R. Cross-matching in liver transplantation. Transplantation 1997;63:789-794.
33. Doyle HR, Marino IR, Morelli F, Doria C, Aldrighetti L, McMichael J, et al. Assessing risk in liver transplantation. Ann Surg 1996;224:168-177.
34. Neumann UP, Lang M, Moldenhauer A, Langrehr JM, Glanemann M, Kahl A, et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001;71:1163-1168.
35. Scornik JC, Soldevilla-Pico C, Van der Werf WJ, Hemming AW, Reed AS, Langham MR Jr, et al. Susceptibility of liver allografts to high or low concentrations of preformed antibodies as measured by flow cytometry. Am J Transpl 2001;1:152-156.
36. Hathaway M, Gunson BK, Keogh AC, Briggs D, McMaster P, Neuberger JM. A positive crossmatch in liver transplantation - no effect or inappropriate analysis? A prospective study. Transplantation 1997;64:54-59.
37. Takaya S, Jain A, Yagihashi K, Nakamura M, Kobayashi K, Takeuchi K, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999;31:2028-2031.
38. Bishara A, Brautbar C, Eid A, Scherman L, Ilan Y, Safadi R. Is presensitization relevant to liver transplantation outcome? Hum Immunol 2002;63:742-750.
39. Muro M, Marin L, Miras M, Moya-Quiles R, Minguela A, Sanchez-Bueno F, et al. Liver recipients harbouring antidonor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transplant Immunol 2005; 14:91-97.
40. Gordon RD, Fung JJ, Markus B, Fox I, Iwatsuki S, Esquivel CO, et al. The antibody crossmatch in liver transplantation. Surgery 1986;100:705-715.
41. Donaldson PT, Alexander GJ, O'Grady J, Neuberger J, Portmann B, Thick M, et al. Evidence for an immune response to HLA class I antigens in the varrishing-bileduct syndrome after liver transplantation. Lancet 1987;1:945-951.
42. Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45:376-379.
43. Mañez R, Kelly RH, Kobayashi M, Takaya S, Bronsther O, Kramer D, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995;21: 1345-1352.
44. Mazariegos GV, Zahorchak A, Reyes J, Chapman H, Girnita A, Macdade K, et al. Immunologic assays in patients successfully withdrawn from immunosuppression (IS) after liver transplantation. Am J Transplant 2004;S8:301.
45. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992;16:671-681.
46. Horne PH, Lunsford KE, Eiring AM, Wang Y, Gao D, Bumgardner GL. CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody. Transplantation 2005;80:514-521.
47. Lorho R, Turlin B, Aqodad N, Triki N, de Lajarte-Thirouard AS, Camus C, et al. C4d: a marker for hepatic transplant rejection. Transplant Proc 2006;38:2333-2334.
48. Schmeding M, Dankof A, Krenn V, Krukemeyer MG, Koch M, Spinelli A, et al. C4d in acute rejection after liver transplantation - a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006;6:523-530.
49. Jain A, Mohanka R, Orloff M, Abt P, Romano J, Bryan L, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant 2006;20:624-633.
50. Dankof A, Schmeding M, Morawietz L, Gunther R, Krukemeyer MG, Rudolph B, et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005;447:87-93.
51. Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005;19: 110-114.